Pictet Asset Management (Switzerland)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | $87.2M | Buy |
924,416
+200,172
| +28% | +$18.9M | 0.1% | 210 |
|
|
2023
Q1 | $73.3M | Buy |
724,244
+142,767
| +25% | +$14.5M | 0.09% | 234 |
|
|
2022
Q4 | $69.5M | Sell |
581,477
-70,401
| -11% | -$8.41M | 0.1% | 229 |
|
|
2022
Q3 | $69.2M | Sell |
651,878
-419,919
| -39% | -$44.6M | 0.1% | 228 |
|
|
2022
Q2 | $104M | Buy |
1,071,797
+296,422
| +38% | +$28.9M | 0.15% | 189 |
|
|
2022
Q1 | $72.7M | Buy |
775,375
+363,942
| +88% | +$34.1M | 0.08% | 254 |
|
|
2021
Q4 | $35M | Sell |
411,433
-938,417
| -70% | -$79.9M | 0.03% | 411 |
|
|
2021
Q3 | $129M | Buy |
+1,349,850
| New | +$129M | 0.14% | 190 |
|